What is the role of baloxavir marboxil (Xofluza) in the treatment of influenza?

Updated: Aug 07, 2020
  • Author: Hien H Nguyen, MD, MS; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

FDA approval of baloxavir was based on the CAPSTONE-1 trial (N=1436). Patients aged 12-64 years were randomized to receive baloxavir, oseltamivir, or placebo. Of the 1064 patients included in the intention-to-treat infected population, the median time to alleviation of symptoms was 53.7 hours in the baloxavir group compared with 80.2 hours for placebo (P< 0.001). Similar results were observed shown with oseltamivir compared with placebo. In addition, the baloxavir group had a significant decrease in viral load after 1 day of treatment compared with both placebo (P< 0.05) and oseltamivir (P< 0.05) groups. [81] It is undetermined whether the rapid drop in viral load decreases the risk of virus transmission.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!